Puma Biotechnology (NASDAQ:PBYI) Share Price Passes Above Two Hundred Day Moving Average of $4.46

Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) shares passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $4.46 and traded as high as $5.30. Puma Biotechnology shares last traded at $5.17, with a volume of 248,185 shares.

Analyst Ratings Changes

PBYI has been the topic of several research analyst reports. HC Wainwright lowered their target price on Puma Biotechnology from $8.00 to $7.00 and set a "buy" rating on the stock in a research note on Friday, March 1st. StockNews.com cut Puma Biotechnology from a "buy" rating to a "hold" rating in a research note on Wednesday, April 10th.

Puma Biotechnology Trading Down 3.5 %

The firm has a market capitalization of $240.57 million, a price-to-earnings ratio of 10.85, a price-to-earnings-growth ratio of 2.90 and a beta of 1.28. The company has a current ratio of 1.57, a quick ratio of 1.50 and a debt-to-equity ratio of 1.23. The company has a fifty day moving average price of $5.70 and a 200-day moving average price of $4.46.

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last announced its quarterly earnings results on Thursday, February 29th. The biopharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.07). The firm had revenue of $72.20 million for the quarter, compared to analyst estimates of $73.22 million. Puma Biotechnology had a net margin of 9.16% and a return on equity of 58.21%. On average, equities research analysts predict that Puma Biotechnology, Inc. will post 0.29 EPS for the current year.

Institutional Investors Weigh In On Puma Biotechnology

Several institutional investors have recently made changes to their positions in PBYI. Vanguard Group Inc. boosted its position in Puma Biotechnology by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 3,802,081 shares of the biopharmaceutical company's stock worth $16,463,000 after purchasing an additional 29,688 shares during the period. Goldman Sachs Group Inc. boosted its position in Puma Biotechnology by 37.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 115,955 shares of the biopharmaceutical company's stock worth $502,000 after purchasing an additional 31,811 shares during the period. Great Point Partners LLC bought a new stake in Puma Biotechnology during the fourth quarter worth approximately $4,734,000. Balyasny Asset Management L.P. bought a new stake in Puma Biotechnology during the fourth quarter worth approximately $354,000. Finally, Sei Investments Co. boosted its position in Puma Biotechnology by 2.2% during the fourth quarter. Sei Investments Co. now owns 291,868 shares of the biopharmaceutical company's stock worth $1,264,000 after purchasing an additional 6,211 shares during the period. 61.29% of the stock is currently owned by institutional investors and hedge funds.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.